Journal
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
Volume 14, Issue -, Pages 211-222Publisher
ELSEVIER
DOI: 10.1016/j.csbj.2016.05.004
Keywords
cell-free DNA; cell-free RNA; cell-free microRNA; cell-free circulating nucleic acids; circulating tumor DNA; circulating mutant DNA
Ask authors/readers for more resources
Tumor heterogeneity is a major challenge and the root cause of resistance to treatment. Still, the standard diagnostic approach relies on the analysis of a single tumor sample from a local or metastatic site that is obtained at a given time point. Due to intratumoral heterogeneity and selection of subpopulations in diverse lesions this will provide only a limited characterization of the makeup of the disease. On the other hand, recent developments of nucleic acid sequence analysis allows to use minimally invasive serial blood samples to assess the mutational status and altered gene expression patterns for real time monitoring in individual patients. Here, we focus on cell-free circulating tumor-specific mutant DNA and RNA (including mRNA and non-coding RNA), as well as current limitations and challenges associated with circulating nucleic acids biomarkers. (C) 2016 Rapisuwon et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available